COBENFY® (xanomeline/trospium)
Schizophrenia
ApprovedApproved in China (Dec 2025)
Key Facts
About Zai Lab
Founded in 2014 by Dr. Samantha Du, Zai Lab has grown into a leading global biopharma with a dual headquarters in China and the U.S. The company combines in-licensed assets with strategic partnerships and internal R&D to build a robust pipeline, with eight products already on the market in China. Its mission is to bridge gaps in global health by advancing breakthrough therapies for patients with significant unmet medical needs.
View full company profileTherapeutic Areas
Other Schizophrenia Drugs
| Drug | Company | Phase |
|---|---|---|
| Luvadaxistat (NBI-1065845) | Neurocrine Biosciences | Phase 2 |
| Cariprazine (Vraylar/Reagila) | Richter Gedeon | Approved |
| Lu AG13909 (PDE10A Inhibitor) | Lundbeck | Phase 1 |
| LATUDA (lurasidone HCl) | Sumitomo Pharma | Approved/Commercial |
| REXULTI (brexpiprazole) | Sumitomo Pharma | Approved/Commercial |
| DSP-2230 (ulotaront) | Sumitomo Pharma | Phase 3 |
| RBP-7000 (risperidone depot) | Indivior PLC | Approved |
| Undisclosed CNS Candidate | Alto Neuroscience | Phase 1 |
| HTL'149 | Nxera Pharma | Phase 1 |
| GPR52 Agonist | Nxera Pharma | Preclinical |
| Fanapt® (iloperidone) | Vanda Pharmaceuticals | Approved |
| Fanapt® (iloperidone) one month injectable | Vanda Pharmaceuticals | In Development |